Differential efficacy of biologic treatments targeting the TNF-alpha/IL-23/IL-17 axis in psoriasis and psoriatic arthritis

摘要

Psoriasis and psoriatic arthritis cause significant physical and psychological burdens for afflicted individuals. An accelerated TNF-alpha/IL-23/IL-17 axis is their major pathomechanism; therefore, anti-TNF-alpha/IL-23/IL-17 biologics are very effective for the treatment of skin and joint lesions in psoriasis and psoriatic arthritis. Given that the IL-17 signature is more upregulated in the skin than in synovium in psoriatic arthritis, anti-IL-23/IL-17 agents seem to be superior to anti-TNF-alpha remedies in the treatment of skin lesions. In this review, we focus on the differential efficacy of anti-TNF-alpha/IL-23/IL-17 biologics in psoriasis and psoriatic arthritis.